Etoposide-Carboplatin (EC) Versus EC Plus Endostar in Patients With Extensive Disease Small Cell Lung Cancer (ED-SCLC): Randomized, Open Label, Placebo-Controlled, Multicentre Study.

Trial Profile

Etoposide-Carboplatin (EC) Versus EC Plus Endostar in Patients With Extensive Disease Small Cell Lung Cancer (ED-SCLC): Randomized, Open Label, Placebo-Controlled, Multicentre Study.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Jan 2015

At a glance

  • Drugs Endostatin (Primary) ; Carboplatin; Etoposide
  • Indications Small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Shandong Simcere Medgenn Bio-Pharmaceutical
  • Most Recent Events

    • 02 Sep 2014 Status changed from active, no longer recruiting to completed, as per ClinicalTrials.gov record.
    • 05 Jun 2012 Results presented at the 48th Annual Meeting of the American Society of Clinical Oncology.
    • 25 Oct 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top